MLKL and Parkinson disease: Building on these findings, we can propose a model (Box 1 in part a of Figure 1) in which RIPK1, RIPK3, and MLKL act as core effectors of necroptosis, while TRADD, CFLAR, and CYLD modulate this pathway in Parkinson’s disease.